Identification of novel candidate proteins for anti-cancer activity of olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine.

Abstrakt

Altered cell control in the rb and p53 pathwazs has emerged as a recurring and underlaying mechanism of most cancer cells.